GSK and Cognizant aim to cut delays in drug-safety reviews, improve traceability and leave medical decisions to specialists.
Back to Top News
Top
October 25, 2026 at 5:42 PM
Seeking Value: GSK’s Drug-Safety AI Strategy Connects Data With Outcomes
Newsweek
Excerpt from Newsweek.